Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

13/04/2023 Panattoni acquires 60,000 sqm land plot to build a data center 16/09/2021 Battery technology in the Barcelona Synchrotron Park environment 06/09/2021 Advances in the creation of a state-of-the-art microscopy platform at the Alba Synchrotron 22/07/2021 IBM, the big blue of technology at the Barcelona Synchrotron Park 02/07/2021 SENER, cutting-edge engineering and technology in the Barcelona Synchrotron Park 11/06/2021 Parc de l'Alba: first injection of landfill gas into the distribution network
1 2 3 4 5 6